Great post Eire2011, that is some shocking data for Baxter's vascular patch.
Baxter is a major player in the field of vascular surgery so if these problems result in Baxters pulling their patch from the market (or surgeons shunning it for safety reasons) this would represent a golden opportunity for us.
I am predicting a very strong launch for VascuCel as vascular surgeons seek to rid themselves of using glutaraldehyde treated patches and all the problems these patches ensue.
VascuCel, page-2
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.35 |
Change
0.000(0.00%) |
Mkt cap ! $352.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 225 | $18.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 1000 | 1 |
View Market Depth
| Last trade - 08.47am 03/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable